Michael E. Severino M.D. — Executive Vice President of Research & Development & Chief Scientific Officer at AbbVie

Mr. Michael E. Severino, also known as Mike, M.D. has been the Chief Scientific Officer and Executive Vice President of Research & Development at AbbVie Inc. since May 15, 2014. Mr. Severino served as a Senior Vice President of Global Development and Corporate Chief Medical Officer at Amgen Inc. since February 14, 2012. He served as the Vice President of Global Development at Amgen. Mr. Severino joined Amgen as Senior Director of Inflammation Early Development. He held the role of Head of Amgen's Proof-of-Concept group within Medical Sciences, where he was responsible for leading a team of physician-scientists responsible for Amgen's late pre-clinical and early clinical programs across all therapeutic areas. In 2006, he assumed leadership of the Inflammation Therapeutic Area in Global Clinical Development and served as its Vice President of Global Development since 2007. Prior to joining Amgen, he held positions of increasing responsibility at Merck Research Laboratories across a wide range of therapeutic areas including Vaccines/Infectious Diseases, Oncology, Diabetes/Metabolic Disorders and Neurosciences. Mr. Severino holds a Doctor of Medicine from The Johns Hopkins University and Postgraduate training in Internal Medicine and Infectious Diseases at Massachusetts General Hospital and Harvard Medical School.